Drug intelligence / Profile preview

QTX6255

Development stage: Preclinical
Lead developer: Quanta Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

QTX6255 is an orally bioavailable, small-molecule pan-KRAS inhibitor being developed by Quanta Therapeutics. It utilizes a unique allosteric modulation approach to restore conformational control of active RAS signaling at the cell membrane. Unlike mutation-specific inhibitors (e.g., G12D or G12V), QTX6255 is designed to target a broad spectrum of KRAS mutations, making it potentially effective across various RAS-driven cancers. The drug is currently in the IND-enabling stage of development.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on QTX6255.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QTX6255.

Explore the full profile